Published in Cell on May 25, 2012
Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene (2017) 0.76
Chronic Iron Limitation Confers Transient Resistance to Oxidative Stress in Marine Diatoms. Plant Physiol (2016) 0.75
The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. Front Aging Neurosci (2016) 0.75
Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biol (2017) 0.75
Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One (2017) 0.75
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 6.31
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet (2004) 12.25
Apoptosis-based therapies for hematologic malignancies. Blood (2005) 2.77
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem (2003) 2.64
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 2.43
Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci (2005) 2.32
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol (2004) 2.03
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J Biol Chem (2006) 1.55
Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem Biol (2004) 1.52
Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol (2011) 1.50
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Targeting the PTPome in human disease. Expert Opin Ther Targets (2006) 1.30
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem (2006) 1.27
Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem (2004) 1.26
The solution structure of the bacterial HSP70 chaperone protein domain DnaK(393-507) in complex with the peptide NRLLLTG. Protein Sci (2003) 1.24
Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex. J Biol Chem (2005) 1.23
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2010) 1.23
Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem Biol (2004) 1.21
Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol (2004) 1.21
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci U S A (2006) 1.13
Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res (2009) 1.12
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2009) 1.11
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther (2009) 1.11
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res (2006) 1.11
Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem (2008) 1.09
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Functional specialization in proline biosynthesis of melanoma. PLoS One (2012) 1.06
A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg Chem (2007) 1.05
SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry (2006) 1.04
MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res (2012) 1.03
Chelator fragment libraries for targeting metalloproteinases. ChemMedChem (2010) 1.02
An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol (2011) 1.01
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
Structure- and fragment-based approaches to protease inhibition. Curr Top Med Chem (2006) 1.01
HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol (2013) 1.00
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett (2008) 1.00
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem (2012) 1.00
Virtual docking approaches to protein kinase B inhibition. J Med Chem (2005) 0.98
NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry (2008) 0.98
A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem Biol (2007) 0.98
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res (2009) 0.98
SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1. J Med Chem (2011) 0.98
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem (2009) 0.98
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol (2012) 0.97
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia (2013) 0.95
Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach. J Med Chem (2009) 0.95
Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. J Med Chem (2008) 0.95
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem (2009) 0.94
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2010) 0.94
Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res (2012) 0.93
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (2012) 0.91
The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities. Oncotarget (2010) 0.91
Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem Biol Drug Des (2008) 0.91
The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry (2006) 0.90
Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. J Med Chem (2007) 0.89
Targeting tumor invasion: the roles of MDA-9/Syntenin. Expert Opin Ther Targets (2014) 0.89
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. Bioorg Med Chem (2009) 0.89
NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem Rev (2014) 0.89
Use of selective Trp side chain labeling to characterize protein-protein and protein-ligand interactions by NMR spectroscopy. J Am Chem Soc (2003) 0.88
NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH. Chem Biol Drug Des (2010) 0.88
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther (2009) 0.88
MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol (2013) 0.88
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase. J Biol Chem (2010) 0.88
Structure-based discovery of a new class of Bcl-xL antagonists. Bioorg Chem (2007) 0.87
Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell Melanoma Res (2011) 0.87
Discovery and binding studies on a series of novel Pin1 ligands. Chem Biol Drug Des (2009) 0.87
Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). J Cell Physiol (2014) 0.86
A structure-based approach to retinoid X receptor-alpha inhibition. J Biol Chem (2006) 0.86
Identification of a novel Mcl-1 protein binding motif. J Biol Chem (2011) 0.86
Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors. Bioorg Med Chem (2009) 0.85
Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem (2014) 0.85
Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11. Pigment Cell Melanoma Res (2012) 0.84
Luminescent silica nanobeads: characterization and evaluation as efficient cytoplasmatic transporters for T-lymphocytes. J Am Chem Soc (2007) 0.84
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. Bioorg Med Chem (2009) 0.84
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors. J Med Chem (2007) 0.83
Structure-based design of covalent Siah inhibitors. Chem Biol (2013) 0.82
A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication. Chem Commun (Camb) (2013) 0.82
The Sam domain of the lipid phosphatase Ship2 adopts a common model to interact with Arap3-Sam and EphA2-Sam. BMC Struct Biol (2009) 0.82
The Nuclear Overhauser Effect in the lead identification process. Curr Drug Discov Technol (2006) 0.82
Solution structure of the first Sam domain of Odin and binding studies with the EphA2 receptor. Biochemistry (2012) 0.81
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J Med Chem (2011) 0.81
Screening multicomponent reactions for X-linked inhibitor of apoptosis-baculoviral inhibitor of apoptosis protein repeats domain binder. J Med Chem (2011) 0.81
Fragment-based drug discovery takes a virtual turn. Nat Chem Biol (2009) 0.80
A novel pharmacophore model for the design of anthrax lethal factor inhibitors. Chem Biol Drug Des (2010) 0.80
Targeting zinc finger domains with small molecules: solution structure and binding studies of the RanBP2-type zinc finger of RBM5. Chembiochem (2011) 0.80
The PTB domain of tensin: NMR solution structure and phosphoinositides binding studies. Biopolymers (2008) 0.79
Small molecule DnaK modulators targeting the beta-domain. Chem Biol Drug Des (2009) 0.79
PDK1 inhibitors. Pharm Pat Anal (2012) 0.79
Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. J Med Chem (2005) 0.79
Design and NMR studies of cyclic peptides targeting the N-terminal domain of the protein tyrosine phosphatase YopH. Chem Biol Drug Des (2010) 0.79
Identification of small molecules that interfere with H1N1 influenza A viral replication. ChemMedChem (2012) 0.79
Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists. Bioorg Chem (2006) 0.79